Question Bank › From candidate to default

From candidate to default

From candidate to default: the company has just been placed inside buyers' own purchasing systems

Calls Tested
498
Answered YES
12
Hit Rate
2.4%
rare by design

Vanda Pharmaceuticals Inc. (VNDA) — this company's answers

NO on the Q4 2021 call 2022-02-23 F
The model's full reasoning — Q4 2021 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”的候选者,转变为“已批准、指定、列入、合格、注册、报销或预先授权”的买家自身采购、报销、处方集、规格、采购、网络、目录或计划系统中的选择——从而公司未来业务的相当一部分现在可以无需为每笔订单进行单独销售活动而到来——并且管理层是否传达了这种准入状态足够新,以至于它所带来的大部分业务量仍将出现在报告结果之后。 在电话会议中,管理层讨论了HETLIOZ在非24小时睡眠-觉醒障碍(Non-24)患者中的报销挑战,以及他们为解决这些挑战所做的努力。具体来说,Tim Williams提到,在诉讼之后,多个州医疗补助计划已修改其标准,取消了失明要求,从而允许HETLIOZ覆盖所有Non-24患者。这似乎是一种准入状态的变化:公司现在被纳入这些州的报销途径,而之前不是。然而,我们需要判断这是否是“最近”的,以及是否大部分业务量尚未实现。 管理层表示,他们正在取得进展,但许多州仍在审查中,而且他们还在努力解决Medicare和商业计划的问题。此外,Kevin Moran提到,2022年的HETLIOZ净产品销售额指引反映了持续的报销挑战,但需求仍远超处方量。这表明,尽管有一些州已改变标准,但整体上,公司尚未完全进入所有支付方的途径,而且业务量尚未完全实现。 然而,问题问的是“公司是否最近从候选者转变为已批准/指定/列入等状态”,并且“这种状态是新的,以至于大部分业务量尚未实现”。在电话会议中,管理层确实描述了某些州医疗补助计划已修改标准,这可以被视为公司被纳入这些计划。但这是否是“最近”的?他们提到“在过去的季度”取得了进展,并且有10个州已修改标准,还有更多州在审查中。这似乎是一个正在进行的过程,而不是一个已经完成并导致业务量大幅增加的状态。 此外,管理层还提到,他们正在努力解决Medicare和商业计划的问题,但尚未解决。因此,整体上,公司尚未完全进入所有支付方的途径。而且,即使在某些州,这种准入状态是否已经导致业务量显著增加?管理层没有明确说业务量已经增加,而是说需求仍远超处方量,这表明准入问题仍然存在。 因此,我认为管理层没有明确描述公司已经“最近”转变为一种状态,使得大部分未来业务无需单独销售活动即可到来。他们描述的是正在进行的努力,以及一些初步的成功,但尚未达到“大部分业务量尚未实现”的程度。此外,这种准入状态可能只是部分州的,而且尚未完全实现。 因此,答案应为NO。

← Back to the full VNDA analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company has RECENTLY crossed from being a candidate that buyers must be persuaded to consider into being an APPROVED, SPECIFIED, LISTED, QUALIFIED, REGISTERED, REIMBURSED, OR PRE-AUTHORIZED choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems — so that a meaningful portion of the company's future business can now arrive WITHOUT a discrete selling event for each order — AND does management convey that this access status is new enough that most of the volume it will unlock is still ahead of the reported results? Answer YES when management's own words convey this ONE phenomenon, in whatever form fits the industry: the company has moved from candidate toward default inside the routine pathway through which purchases get made. Example forms, all treated equally: being named to an approved or preferred supplier list, procurement schedule, purchasing program, or payer network; being written into specifications, standards, reference designs, configurations, protocols, or bundled defaults; being added to a formulary, reimbursement catalog, coding/payment pathway, formulary-like listing, or provider directory; being qualified onto a customer's, agency's, platform's, or program's roster; or comparable status that inserts the company into the system through which transactions routinely flow. The essential point is the EXCHANGE OF FRICTION STATUS: buying no longer has to be re-argued each time, because the company is now inside the pathway. For YES, management must also convey, directly or plainly in substance, that the status is recent and the flow through it is only beginning — so the results just reported capture little of what this access will bring. One such gateway, or several together, both qualify. Answer NO if the only access described is ordinary selling relationships, routine reseller/distribution agreements, or standard customer wins where each order still must be individually persuaded. NO if the relevant status has existed for years and is simply the company's steady way of going to market, with nothing new about the access. NO if the status is only pending, applied for, hoped for, or contingent on approvals not yet obtained. NO if management merely asserts that the product is "mission-critical," "a standard," or "the default choice" without describing a concrete buyer-side system the company has been placed into. NO if the business flowing through that status is already mature and substantially reflected in current results. NO if the access status or its significance appears only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
INGN Inogen, Inc. Q1 2023 2023-05-05 F
HBB Hamilton Beach Brands Holding Company Q3 2022 2022-11-05 C
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
MGNI Magnite, Inc. Q1 2022 2022-05-04 D
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C

How the model reasoned

PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.

More from the question bank

Paying a named price today to serve businessEarnings outrunning the activityAnalysts converge on an emerging driverWorking harder than they are being paid forNumbers reset the ceilingDeliberately different by designAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.